

# **KERN FAMILY HEALTH CARE MEETING OF THE PHARMACY AND THERAPEUTICS COMMITTEE AGENDA**

---

**DATE:** January 26, 2005  
**TIME:** 6:30 P.M.  
**PLACE:** Hodel's Restaurant,  
5917 Knudsen Drive (Hwy 99 and Olive Drive) B  
Bakersfield, Ca. 93308

The Agenda is divided into three sections:

**CORRESPONDENCE AND CONSENT CALENDAR:** These matters include routine non-policy financial and administrative actions, may include correspondence, and are usually approved by a single majority vote. Any Committee Member may remove an item from the correspondence and consent calendar.

**REGULAR CALENDAR:** These items include significant financial, administrative and policy matters.

**CLOSED SESSION:** These items include contracting, peer review, personnel and litigation matters and other issues to be discussed by Committee members only, with report to the public on any action taken.

## **REGULAR AGENDA CORRESPONDENCE AND CONSENT CALENDAR**

1. Approval of the Minutes of September 29, 2005 meeting.
2. Approval of Medicare current practices
3. Approval of the following recommended additions/changes to the Formulary:
  - a. Atrovent HFA – only form available
  - b. Phoslo – caps vs. tabs
  - c. Pulmicort Turbuhaler – 200 doses
  - d. Premarin 0.45 mg. – extension of line
  - e. Bacitracin – Neosporin

## **REGULAR CALENDAR**

### **I. PUBLIC COMMENT**

This portion of the meeting is reserved for persons to address the Committee on any matter not on this agenda but under the jurisdiction of the Committee. They may ask a question for clarification, make a referral to staff for factual information or request staff to report back to the Committee at a later meeting.

Also, the Committee may take action to direct the staff to place a matter of business on a future agenda.

**SPEAKERS ARE LIMITED TO TWO MINUTES. PLEASE  
STATE YOUR NAME BEFORE MAKING YOUR  
PRESENTATION. THANK YOU!**

## **II. Action Items**

Discussion and Possible Action Regarding Formulary Changes to the following:

1. DUR:
  - a. general – trends
    1. Therapeutic duplication
    2. b-agonist
  - b. Changes to dosage
- 2 Antibiotic protocol guidelines.
3. Discussion and possible action regarding Oral Contraceptive
  - a. Ortho-Tricyclen Lo
  - b. Yasmin
  - c. Biphasics
4. Ace Inhibitors/ARB Utilization Review
5. Triptans dosing/utilization cost review

## **III. Adjourn**

## **IV. Closed Session**

1. Closed Session Regarding Peer Review  
(California and Welfare Institutions Code  
Section (14087.38(n))
  - a. Closed Session to discuss and discharge its responsibility to evaluate and improve the quality of care rendered by health facilities and Health practitioners.
2. Closed Session Regarding Provider Rates and Contracts  
(California Welfare and Institutions Code Section 14087.38(m))
  - a. Closed session to consider and take action of matters pertaining to contracts, and contract negotiations with providers of health care services concerning all matters related to rate of payment.)

Next Regular meeting is scheduled for April 2006.

---

PLEASE NOTE: Anyone wishing information on the Kern Health Systems Pharmacy & Therapeutics Committee Agendas should contact Bruce Wearda, R.Ph., Corporate Pharmacist, at Kern Health Systems either by telephone at (661)664-5100 or in writing at the following address:

Kern Health Systems  
9700 Stockdale Hwy  
Bakersfield, CA 93311

Such requests must be received no later than 5:00 p.m. ten (10) calendar days prior to the next regularly scheduled Committee Meeting.